HOW DO WE FOLLOW THE GUIDELINES IN THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES?/TIP 2 DIYABETLI HASTALARIN TEDAVISINDE KILAVUZLARA NE KADAR UYGUN HAREKET EDIYORUZ?

Objective: We aimed to retrospectively investigate compliance with guidelines in order to increase the awareness of physicians towards current treatment approaches and goals in Type 2 diabetes mellitus (DM). Material and Method: Our study was designed as a retrospective, cross-sectional, analytical study. Patients who received treatment for Type 2 DM between January 2018 and January 2019 were randomly identified. Laboratory values, accompanying diseases, and medications used by the patients in their last one-year follow-up were recorded. Results: A total of 1,154 patients were included in the study. When the patients who came for regular check-ups every three months and those who did not were compared, there was no statistically significant difference between the initial hemoglobin A1c (HbA1c) and the final values (7.83% [+ or -] 1.94% and %7.99% [+ or -] 1.97%). At the end of one year, HbA1c values were statistically significantly lower than those of patients who did not come for control (7.18% [+ or -] 1,.5% and 7.91% [+ or -] 1.96%). 887 (76.8%) of a total of 1154 patients were using metformin regularly. In 149 of our patients, the initial HbA1c level was above 10% and insulin treatment was started immediately in 120 (80.5%) of these patients. Conclusion: In patients with Type 2 Diabetes, the frequency of follow-up and regulation of metformin and insulin treatment is generally good, but the use of GLP-1 receptor agonists or SGLT2 inhibitors, which are new anti-diabetic drug groups, is low. The rate of adding secondary therapy in dyslipidemic patients who do not achieve the targeted results with statin therapy has been found to be very low. Keywords: Treatment of diabetes, guidelines, diabetes, insulin Amac: Biz bu calisma ile, Tip 2 diabetes mellitusta (DM) guncel tedavi yaklasimlari ve hedeflere yonelik hekimlerin farkindaligini artirmak icin retrospektif olarak kilavuzlara uygunlugu arastirmayi hedefledik. Gerec ve Yontem: Calismamiz retrospektif, kesitsel, analitik bir calisma olarak tasarlandi. Ocak 2018-Ocak 2019 tarihleri arasinda Tip 2 DM nedeniyle tedavi alan hastalar, randomize olarak tespit edildi. Hastalarin son bir yillik takiplerindeki laboratuvar degerleri, eslik eden hastaliklari ve kullandiklari ilaclar kaydedildi. Bulgular: Calismaya toplam 1154 hasta dahil edilmistir. Uc ayda bir duzenli kontrole gelenler ile gelmeyenler karsilastirildiginda, baslangic hemoglobin A1c (HbA1c) degerleri arasinda istatistiksel olarak anlamli bir fark sapt